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1. DISEASE CHARACTERISTICS
1.1 Name of the disease (synonyms)
Rothmund–Thomson syndrome
Poikiloderma atrophicans with cataract
1.2 OMIM# of the disease
#268400
1.3 Name of the analyzed genes or DNA/chromosome segments
RECQL4 (RECQ-like, type 4), RECQ4
1.4 OMIM# of the gene(s)
*603780
1.5 Mutational spectrum
Biallelic mutations in the RECQL4 gene are associated with
Rothmund–Thomson (RTS) and two additional recessive disorders:
RAPADILINO (RAdial hypoplasia, PAtellae hypoplasia and cleft or
arched PAlate, DIarrhea and DIslocated joints, LIttle size and LImb
malformation, slender NOse and NOrmal intelligence) and Baller–
Gerold syndrome (BGS). More than 60 disease-causing mutations
have been reported, of which at least 40 have been detected in RTS
patients.1,2 The types of observed mutations are as follows, in order of
decreasing prevalence: nonsense or frameshift mutations; splicing
alterations, including substitutions at canonical splice junctions or at
splice-site consensus sequences and subtle intronic deletions that
reduce intron size below the threshold (o80 bp) required for correct
splicing;3,4 and missense mutations. There are a few recurrent
mutations, among which the most common, exon 9 c.1573delT
(p.Cys525AlafsX33), has been detected in patients with all three
RECQL4-associated diseases. This truncating mutation accounts for
approximately one-third of RTS mutations and has only been found
in compound heterozygous patients from multiple ethnic
backgrounds. A deletion of the entire gene has never been identified.
1.6 Analytical methods
Bidirectional sequencing of all exonic and intronic sequences of the
RECQL4 gene.
MLPA (multiplex ligation-dependent probe identification) should
be applied if sequencing fails to identify both mutant alleles.
Conventional cytogenetics may unveil a high rate of spontaneous
and induced chromosomal breakage, as well as mosaic trisomies and
isochromosomes.5,6,7
1.7 Analytical validation
Bidirectional sequencing results are confirmed by sequencing using
different sets of primers. Pathogenicity of novel missense alterations
must be verified by testing a set of at least 100 control chromosomes
of the same ethnic origin and by in silico prediction methods. RT-PCR
and cDNA sequencing is performed to confirm splicing mutations
and to rule out effects on splicing by missense mutations. Testing of
parents for carrier status should be performed in all cases.
1.8 Estimated frequency of the disease
(incidence at birth (‘birth prevalence’) or population prevalence)
If known to be variable between ethnic groups, please report:
The population prevalence of RTS syndrome is unknown. RTS
is a very rare disorder, with fewer than 400 cases described in the
literature.
However, RTS is likely to have been under-diagnosed because of the
lack of awareness of this disorder and the lack of signs unique to the
syndrome. Moreover, incidences relate directly to clinicians’ and
clinical geneticists’ knowledge about the syndrome.
1.9 Diagnostic setting
Yes No
A. (Differential) diagnostics 2 &
B. Predictive testing & 2
C. Risk assessment in relatives 2 &
D. Prenatal 2 &
Comment: The main diagnostic sign of RTS is poikiloderma
(telangiectasic lesions, reticulated areas of depigmentation, hyperpig-
mentation, and punctate atrophy), which appears within the first 2
years of life as a chronic lesion evolving from a previous acute
erythematous rash, first affecting the face and then extending to the
limbs. Another hallmark is growth delay, present in 2/3 of patients,
which is noted in the prenatal setting (ie, intrauterine growth
restriction) and persists harmoniously after birth along at least—2
SD (when compared with the normal population). Given the high
number of genodermatoses that present with poikiloderma, the pattern
of presentation should be carefully considered, as should the
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concomitance of other common RTS signs: radial-ray defects; growth
delay; sparse hair. Although Poikiloderma with Neutropenia (PN)
syndrome, in many previous cases misdiagnosed as RTS, can now be
diagnosed with a specific genetic test, clinically diagnosed RTS patients
still comprise subgroups of unknown molecular etiology, including
those characterized by poikiloderma and cataract, often without bone
defects. Ambiguities resulting from partial clinical overlap with
Fanconi Anemia (FA), Werner syndrome (WS), and Dyskeratosis
Congenita (DC) can be resolved by the RECQL4 test; however, this
may leave open the differential diagnosis with other RECQL4-related
diseases, particularly RAPADILINO syndrome.8,9 This test should be
offered to all juvenile osteosarcoma cases with poikiloderma-like
lesions.
2. TEST CHARACTERISTICS
Genotype or disease A: True positives
B: False positives
C: False negative
D: True negative
Present Absent
Test
Positive A B Sensitivity:
Specificity:
A/(AþC)
D/(DþB)
Negative C D Positive predictive value:
Negative predictive value:
A/(AþB)
D/(CþD)
2.1 Analytical sensitivity
(proportion of positive tests if the genotype is present)
Depends on the method(s) used. The analytical sensitivity could be
495%, but only if the DNA test is not restricted to exon sequencing.
This applies to all three RECQL4-associated diseases.
2.2 Analytical specificity
(proportion of negative tests if the genotype is not present)
495%
2.3 Clinical sensitivity
(proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors, such as
age or family history. In such cases, a general statement should be
given, even if quantification can only be made on a case by case basis.
The age of onset and range of clinical features is variable, but
the main clinical signs should be present by the age of 2 years. By
sequence analysis, including complete sequencing of all exons and
introns, a disease-causing mutation is identified in B66% of
individuals diagnosed with RTS.10 Incomplete clinical sensitivity
could be explained by: (i) locus heterogeneity; (ii) mutations within
the promoter of the gene; or (iii) mutations not identifiable by direct
sequencing, such as deletions of entire exons or of the entire gene.
Indeed, in a few patients (5 out of 64 listed in Siitonen et al.1), only
one RECQL4 mutation is detectable.
2.4 Clinical specificity
(proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors, such as
age or family history. In such cases, a general statement should be
given, even if quantification can only be made on a case by case basis.
Close to 100%.
2.5 Positive clinical predictive value
(life time risk to develop the disease if the test is positive)
Hundred percent for pathogenic mutations. On the basis of the
literature and the reported pedigrees, all cases manifest the disease at
early infancy: the penetrance is complete by at the age of 2 years, with
variable expressivity. For patients who test positive for mutations,
genetic counseling and surveillance should be provided for increased
risk of osteosarcoma at an early age, and epithelial carcinoma of the
skin in adulthood.11,12 Prevalences of osteosarcoma and skin cancer in
RTS are 30% and 5%, respectively. However, it must be considered
that a few mutations detected in RTS patients are shared by
RAPADILINO and BGS, which represent allelic disorders with
different medical complications and cancer susceptibility.1
2.6 Negative clinical predictive value
(probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected
person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested:
If the index case in that family has been tested and found positive,
a negative test in a familial non-affected person would exclude an
increased risk of disease (negative clinical predictive value close to
100%).
Index case in that family had not been tested:
Under this condition, it would be inappropriate to test potentially
at-risk family members before 2 years of age, by which time 90% of
the cases manifest the disease. A preliminary step would be to test
both parents of the index case to assess their carrier status.
3. CLINICAL UTILITY
3.1 (Differential) diagnostics: The tested person is clinically
affected
(To be answered if ‘A’ was marked in 1.10)
In classic cases, the correct diagnosis is based on clinical presenta-
tion with early-onset facial poikiloderma and radial-ray defects. In
borderline or atypical cases, the differential diagnosis with syndromes
with overlapping features, such as PN, DC, and WS, should be
considered to orient the genetic test. This problem is overlooked in
cases whose clinical evaluation suggests the allelic RAPADILINO or
BG disorders. Molecular testing allows for the correct diagnosis,
which is necessary for accurate targeting of syndrome-specific
oncosurveillance.
3.1.1 Can a diagnosis be made other than through a genetic test?
No & (continue with 3.1.4)
Yes 2
Clinically 2
Imaging &
Endoscopy &
Biochemistry &
Electrophysiology other (please describe) &
3.1.2 Describe the burden of alternative diagnostic methods to the
patient
No single alternative diagnostic method can be envisaged: rather, a
panel of clinical-instrumental exams, including skin inspection by a
dermatologist experienced in genodermatoses, baseline skeletal radio-
graphs, and eye examination, would allow the formulation of a
correct diagnosis.
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3.1.3 How is the cost effectiveness of alternative diagnostic methods
to be judged?
A genetic diagnosis permits the patient to avoid continuous and
inconclusive clinical evaluations accompanied by multiple instrumen-
tal examinations. The cost effectiveness of alternative diagnostic
methods is lower than that of the genetic test.
3.1.4 Will disease management be influenced by the result of a
genetic test?
No &
Yes 2
Therapy
(please
describe)
Pulsed-dye laser photocoagulation to improve the telangiec-
tasic component of the rash. Routine treatment with growth
hormone, GH, (only for RTS cases with documented GH
deficiency). Treatment of periodontitis in early infancy. Surgi-
cal options include the removal of cataracts, usually developed
by patients without RECQL4 mutations, and the excision of
osteosarcoma or cutaneous tumors, often found in RECQL4-
mutated patients.
The potential risk of radiation exposure from radiologic
screening for osteosarcoma is under debate, given the modest
sensitivity of cells from RECQL4-mutated patients to DNA-
damaging agents.12
A study on the response to therapy for osteosarcoma in
patients with RTS indicated that these patients do not present
the same level of sensitivity to genotoxic agents as patients
with other chromosomal instability disorders. Therefore, they
should be treated initially with conventional doses. However,
caution and careful clinical observation is warranted,
especially regarding monitoring for enhanced doxorubicin
sensitivity and side effects in the form of mucositis.14 By
contrast, cisplatin (to which RECQL4-deficient fibroblasts are
less sensitive compared with doxorubicin13) can replace
doxorubicin as an active chemotherapy agent, as it causes no
apparent increased toxicity.14
The histological response of osteosarcoma to standard
chemotherapy and the clinical outcome are similar between
RTS and non-RTS patients, with a 5-year survival rate of 60–
70%.14 After treatment, a prolonged period of follow-up is
recommended. This recommendation is made not only for
metastasis, which is predominantly pulmonary, but also for the
occurrence of a second malignancy, which has been reported
in a significant proportion of RTS tumor carriers.11
Prognosis
(please
describe)
Although some clinical signs and recent breakthroughs
regarding the pathways compromised by RECQL4 defects15
suggest precocious aging, the patient’s lifespan is not altered,
provided that the neoplastic disease is diagnosed and treated
in time. Lifespan in the absence of malignancy is probably
normal, although follow-up data in the literature are limited.
RECQL4-positive patients exhibit a significant correlation
between mutational status and skeletal abnormalities16 and
are highly predisposed to development of osteosarcoma, even
multicentric, with a mean age of onset of 14.03 years.
Epithelial tumors (most notably squamous cell carcinoma) of
the skin are well represented in adult RTS patients (onset at a
mean age at 34.4 years): however, the correlation of these
tumors with the molecular subclass remains undefined.
Management
(please
describe)
Genetic testing should be accompanied by appropriate genetic
counseling to ensure early identification and treatment of
syndrome-associated manifestations. Owing to increased
photosensitivity observed in a few instances, patients should be
advised to use sunscreens. A multidisciplinary team is needed
(Continued )
to offer long-term follow-up and treatment to RTS patients.
This team should include a dermatologist, an orthopedic
surgeon, an ophthalmologist, and an oncologist. Annual phy-
sical examination of patients should include thorough exam-
ination of the skin to follow the onset and features of
poikiloderma; eye examination because of an increased inci-
dence of cataracts; oral examination because of an increased
incidence of caries; malocclusion, early-onset periodontitis,
and dental radiographic screening for dental abnormalities; and
baseline skeletal radiographs by the age of 5 years to define
underlying skeletal dysplasias. Specific attention must be paid
to cancer surveillance, which should be provided at follow-up of
RECQL4-mutated patients to monitor bone pain, swelling, an
enlarging lesion on a limb suggestive of a bone tumor, or skin
lesions with unusual color or texture.
3.2 Predictive setting: The tested person is clinically unaffected but
carries an increased risk based on family history
(To be answered if ‘B’ was marked in 1.10)
3.2.1 Will the result of a genetic test influence lifestyle and
prevention?
If the test result is positive (please describe).
If the test result is negative (please describe).
3.2.2 Which options in view of lifestyle and prevention does an at-
risk person have if no genetic test has been done (please describe)?
3.3 Genetic risk assessment in family members of a diseased person
(To be answered if ‘C’ was marked in 1.10)
3.3.1 Does the result of a genetic test resolve the genetic situation in
that family?
Yes, if causative mutations have been identified in RECQL4, it is
possible to assess the carrier status of all unaffected family members
and to offer genetic counseling to the family.
3.3.2 Can a genetic test in the index patient save genetic or other
tests in family members?
Yes. However, if the result is negative or uncertain, testing of family
members is not recommended.
3.3.3 Does a positive genetic test result in the index patient enable a
predictive test in a family member?
Infrequently, given the early onset of the disease (before the age of 2
years).
3.4 Prenatal diagnosis
(To be answered if ‘D’ was marked in 1.10)
3.4.1 Does a positive genetic test result in the index patient enable a
prenatal diagnosis?
Yes, provided that both disease-causing alleles have been identified in
an affected family member and their segregation from obligate carrier
parents has been traced.
4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate
medical consequences. Is there any evidence that a genetic test is
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nevertheless useful for the patient or his/her relatives? (Please
describe)
Genetic testing has no immediate medical consequences for healthy
carriers. However, carriers’ awareness of their genetic status is
important for family planning.
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